{"filings":[{"id":96756,"accession_number":"0001493152-26-021629","cik":1922335,"company_name":"Syra Health Corp","ticker":"SYRA","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Syra Health posts first profitable quarter in Q1 2026; net income $241K, EPS $0.02, revenue up 22%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income of $241,000 vs net loss of $(472,265) in Q1 2025; EPS $0.02 vs ($0.04).","Total revenue $2.3M (+22% YoY); population health solutions grew 46% to $1.8M.","Gross margin expanded to 42.7%, up 11 ppt from 31.7%.","Cash on hand $2.9M; no long-term debt as of March 31, 2026.","Adjusted EBITDA improved to $244,495 from $(462,239) in prior year."],"consensus_eps_estimate":null,"consensus_eps_actual":0.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":2273520.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5969583.778014941,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110952,"accession_number":"0001493152-26-009799","cik":1922335,"company_name":"Syra Health Corp","ticker":"SYRA","form_type":"8-K","filed_at":"2026-03-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Syra Health FY2025 net loss down 76%; Population Health revenue up 157% to $5.3M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2025 revenue $7.2M (-9% YoY); net loss improved 76% to ($896K) from ($3.8M).","EPS improved to ($0.08) from ($0.50) in FY2024; Q4 2025 net loss ($135K) vs ($504K) Q4 2024.","Population Health revenue grew 157% to $5.3M; gross margin expanded to 34.4% from 20.7%.","Operating expenses down 37% to $3.4M; adjusted EBITDA improved to ($863K) from ($3.7M).","Company expects profitability by year-end 2026; cash $1.6M, no long-term debt."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":5969583.778014941,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127583,"accession_number":"0001493152-25-028301","cik":1922335,"company_name":"Syra Health Corp","ticker":"SYRA","form_type":"8-K","filed_at":"2025-12-18T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Syra Health appoints Gregory R. Alexander as CEO effective Jan 5, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["New CEO Gregory R. Alexander receives $251k base salary, 30% target bonus, and 110,537 RSUs.","Also granted 257,920 stock options (Class B) and 368,458 performance stock units.","Alexander previously served as SVP at Ellipsis Health, Chief Growth Officer at CitizensRx (tripled sales), and market leader at Lumeris (expanded from 3 to 11 markets).","He will replace interim CEO Priya Prasad; appointment follows an extensive national search.","Alexander is a former U.S. Marine Corps officer with over 20 years of P&L experience in healthcare."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5969583.778014941,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127582,"accession_number":"0001493152-25-024059","cik":1922335,"company_name":"Syra Health Corp","ticker":"SYRA","form_type":"8-K","filed_at":"2025-11-18T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Syra Health amends charter to modify Class B conversion triggers and transfer rules","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved charter amendments on Nov 14, 2025; Certificate of Amendment filed and effective Nov 18, 2025.","Removed provision requiring automatic conversion of Class B common stock upon death of a Class B stockholder.","Expanded permissible transferees for Class B shares without conversion to include immediate family, heirs, successors, and assigns."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":5969583.778014941,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127581,"accession_number":"0001493152-25-023488","cik":1922335,"company_name":"Syra Health Corp","ticker":"SYRA","form_type":"8-K","filed_at":"2025-11-14T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Syra Health shareholders approve Class B charter amendments and elect directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All five director nominees elected; top vote-getter Priya Prasad 9,093,067 for, 4,508,108 against.","Ratified M&K CPAs as auditor: 14,955,596 for, 369,733 against, 523,081 abstain.","Approved amendment to delete automatic conversion of Class B shares on death: 8,917,010 for, 4,632,013 against.","Approved amendment allowing transfer of Class B shares to family members: 8,880,105 for, 4,631,020 against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.15,"market_cap_usd":5969583.778014941,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127580,"accession_number":"0001493152-25-021784","cik":1922335,"company_name":"Syra Health Corp","ticker":"SYRA","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Syra Health Q3 revenue falls 26% to $1.7M; population health up 96%, net loss down 46%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $1.7M, down from $2.3M YoY due to federal spending cuts.","Population Health segment grew 96% YoY to $1.28M.","Gross margin improved 300 bps to 33%; net loss narrowed 46% to ($225,902).","EPS improved to ($0.02) from ($0.06); adjusted EBITDA improved to ($218,601).","Cash $2.0M, no long-term debt; SyraBot live with managed care org serving 400k members."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":5491944.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5969583.778014941,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144363,"accession_number":"0001641172-25-024383","cik":1922335,"company_name":"Syra Health Corp","ticker":"SYRA","form_type":"8-K","filed_at":"2025-08-15T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Syra Health appoints Radhika Mereddy to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Radhika Mereddy appointed to Syra Health's Board on August 13, 2025.","Compensation consistent with other non-employee directors.","No arrangement or understanding with any person regarding her selection.","Mereddy is a principal stockholder in RAD CUBE LLC, STVentures, NLogix IT, and SKL Demand."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":5969583.778014941,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144362,"accession_number":"0001641172-25-023118","cik":1922335,"company_name":"Syra Health Corp","ticker":"SYRA","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Syra Health Q2 net loss narrows 95% to $64K; gross margin surges to 38.7%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $64K ($0.01 EPS) vs $1.4M loss ($0.21 EPS) in Q2 2024; adjusted EBITDA improved to ($54K) from ($1.4M).","Gross margin rose 2,090 bps to 38.7%; operating expenses declined 53% YoY to $816K.","Population Health revenue up 197% to $1.6M, driven by $5.8M FSSA contract for HCBS training.","Cash $2.3M, no long-term debt; negotiating $5.8M CMHW mental health contract with Indiana FSSA."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":3803973.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5969583.778014941,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144361,"accession_number":"0001641172-25-021576","cik":1922335,"company_name":"Syra Health Corp","ticker":"SYRA","form_type":"8-K","filed_at":"2025-07-30T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Deepika Vuppalanchi resigns from Syra Health board for personal reasons","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Deepika Vuppalanchi resigned from the Board of Directors on July 28, 2025, for personal reasons.","Vuppalanchi continues as Chief Executive Officer; her board resignation does not affect her executive role.","The company did not announce any replacement director or board committee changes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":5969583.778014941,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162718,"accession_number":"0001641172-25-015349","cik":1922335,"company_name":"Syra Health Corp","ticker":"SYRA","form_type":"8-K","filed_at":"2025-06-17T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Syra Health terminates CEO Deepika Vuppalanchi for cause; CFO appointed interim CEO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board terminated CEO Deepika Vuppalanchi for cause on June 13, 2025.","Priya Prasad, previously CFO and COO, appointed interim CEO effective June 16, 2025.","Termination of employment agreement dated April 5, 2021 for cause."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5969583.778014941,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162717,"accession_number":"0001641172-25-011732","cik":1922335,"company_name":"Syra Health Corp","ticker":"SYRA","form_type":"8-K","filed_at":"2025-05-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Syra Health board launches national CEO search; Vuppalanchi interim","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board initiates a national search for a new CEO to succeed current CEO Dr. Deepika Vuppalanchi.","Dr. Vuppalanchi will serve as interim CEO until a successor is appointed.","Co-founder Vuppalanchi is expected to remain on the leadership team post-transition.","Transition is described as a strategic succession plan for next growth phase."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5969583.778014941,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162716,"accession_number":"0001641172-25-009292","cik":1922335,"company_name":"Syra Health Corp","ticker":"SYRA","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Syra Health Q1 revenue $1.9M (+6% YoY); net loss narrows to ($472K); withdraws 2025 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $1.9M (+6% YoY); Population Health revenue tripled to $1.2M.","Gross margin improved to 31.7% (was 17.1%) on shift to higher-margin contracts.","Operating expenses fell 39% to $1.1M; net loss narrowed to ($472K) from ($1.4M).","Withdrew 2025 guidance due to federal budget uncertainty impacting key customers.","Cash $2.5M, no debt; secured $2.5M insurance contract, $1.5M extension with Indiana FSSA."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":1857774.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5969583.778014941,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162715,"accession_number":"0001641172-25-008103","cik":1922335,"company_name":"Syra Health Corp","ticker":"SYRA","form_type":"8-K","filed_at":"2025-05-01T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Andrew Dahlem resigns from Syra Health board for personal reasons","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Andrew Dahlem resigned from the Board of Directors on April 25, 2025.","Resignation cited personal reasons; no explanation beyond that was provided.","No replacement director has been named as of the filing date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":5969583.778014941,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162714,"accession_number":"0001641172-25-003154","cik":1922335,"company_name":"Syra Health Corp","ticker":"SYRA","form_type":"8-K","filed_at":"2025-04-08T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Andrew Dahlem appointed Chairman of the Board at Syra Health","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Andrew Dahlem agreed to become Chairman of the Board.","The appointment became effective April 7, 2025.","Mr. Dahlem is a current director of Syra Health Corp."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":5969583.778014941,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":180690,"accession_number":"0001493152-25-009882","cik":1922335,"company_name":"Syra Health Corp","ticker":"SYRA","form_type":"8-K","filed_at":"2025-03-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Syra Health FY 2024 revenue $8.0M (+45% YoY); Q4 net loss nearly halved to $504K; PopHealth up 132%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY 2024 revenue $8.0M (+45% YoY); net loss $3.8M vs $2.9M in 2023.","Q4 2024 revenue $2.0M (+14% YoY); net loss $504K vs $995K (halved YoY).","Population Health revenue $1.7M in 2024 (+132% YoY); Q4 PopHealth up 285% YoY.","Cash $2.4M, no long-term debt; 2025 guidance low double-digit % revenue growth.","Secured contract extensions: Indiana $1.5M, Tennessee $450K (up to $1.3M), DC $1M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5969583.778014941,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":180689,"accession_number":"0001493152-25-002656","cik":1922335,"company_name":"Syra Health Corp","ticker":"SYRA","form_type":"8-K","filed_at":"2025-01-17T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Syra Health Executive Chairman and President Sandeep Allam passes away","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Notified on January 15, 2025 of Sandeep Allam's death.","Allam served as Executive Chairman and President.","No replacement or interim successor has been announced.","Company has not disclosed any operational or strategic impact."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":5969583.778014941,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197517,"accession_number":"0001493152-24-043326","cik":1922335,"company_name":"Syra Health Corp","ticker":"SYRA","form_type":"8-K","filed_at":"2024-11-01T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Syra Health regains Nasdaq compliance on minimum equity requirement","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq deficiency notice Aug 13, 2024 for failing minimum $2.5M stockholders' equity.","As of Sep 30, 2024, stockholders' equity was $3,330,653, exceeding threshold.","Nasdaq Staff determined compliance is now met; matter closed.","Company will continue trading on Nasdaq."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5969583.778014941,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197516,"accession_number":"0001493152-24-042779","cik":1922335,"company_name":"Syra Health Corp","ticker":"SYRA","form_type":"8-K","filed_at":"2024-10-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Syra Health reports Q3 2024 revenue $2.3M (+42% YoY); net loss narrows 69% sequentially to $417K","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $2.3M, up 42% YoY from $1.6M; Population Health +36%, Healthcare Workforce +54%.","Net loss $417,535 ($0.06 EPS) vs $1.4M ($0.21) in Q2 2024, a 69% reduction quarter-over-quarter.","Gross margin improved to 29.7% from 17.8% in Q2 2024; operating expenses cut 37% sequentially.","Cash $2.7M with no long-term debt; management targets profitability in 2025.","Launched Syrenity mental health app; secured $5.8M Indiana training contract with revenue starting Q4 2024."],"consensus_eps_estimate":-0.2142,"consensus_eps_actual":-0.48,"consensus_revenue_estimate":null,"consensus_revenue_actual":5975357.0,"consensus_period":"2024-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5969583.778014941,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197515,"accession_number":"0001493152-24-041772","cik":1922335,"company_name":"Syra Health Corp","ticker":"SYRA","form_type":"8-K","filed_at":"2024-10-21T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Syra Health receives Nasdaq delisting notice for bid price below $1.00 for 30 consecutive days","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Syra Health on Oct 18, 2024 that its common stock bid price closed below $1.00 for 30 business days, violating Listing Rule 5550(a)(2).","Company has 180 calendar days, until April 16, 2025, to regain compliance by achieving $1.00 closing bid for at least 10 consecutive business days.","If non-compliance continues, Syra may seek a second 180-day period or appeal a delisting determination to a Nasdaq hearings panel.","Common stock (SYRA) continues trading on Nasdaq during the cure period; company may consider options such as a reverse stock split.","No assurance the company will maintain its Nasdaq listing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5969583.778014941,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":213738,"accession_number":"0001493152-24-032692","cik":1922335,"company_name":"Syra Health Corp","ticker":"SYRA","form_type":"8-K","filed_at":"2024-08-15T23:59:59+00:00","items":["3.01","7.01"],"status":"ready","headline":"Syra Health receives Nasdaq delisting notice for equity shortfall; provides 2024 revenue guidance of $7.5-9.5M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Nasdaq notified Syra Health of non-compliance with stockholders' equity minimum of $2.5M (Listing Rule 5550(b)(1)).","Company has 45 days to submit a compliance plan; Nasdaq may grant up to 180-day extension.","Full-year 2024 revenue forecast $7.5-9.5M (36%-73% YoY growth), with majority in H2 due to delayed implementation.","If compliance plan not accepted, stock could be delisted; company can appeal."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":5969583.778014941,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":213737,"accession_number":"0001493152-24-030963","cik":1922335,"company_name":"Syra Health Corp","ticker":"SYRA","form_type":"8-K","filed_at":"2024-08-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Syra Health Q2 revenue $2.0M (+101% YoY); net loss widens to $1.4M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $2.0M vs $1.0M in Q2 2023; Population Health grew 276% YoY, Healthcare Workforce 66%.","Gross margin improved to 17.8% from 13.1% on mix shift toward higher-margin population health.","Net loss of $1.4M compared to $802.8K loss in Q2 2023; Adjusted EBITDA -$1.3M vs -$771K.","Cash $1.6M and no long-term debt; 25% reduction in executive pay implemented starting Q3 2024.","Subcontractor on $43B DHA workforce contract vehicle; $5.8M Indiana health education contract."],"consensus_eps_estimate":-0.1938,"consensus_eps_actual":-0.43,"consensus_revenue_estimate":null,"consensus_revenue_actual":3722021.0,"consensus_period":"2024-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5969583.778014941,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":232956,"accession_number":"0001493152-24-024283","cik":1922335,"company_name":"Syra Health Corp","ticker":"SYRA","form_type":"8-K","filed_at":"2024-06-18T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Syra Health Corp. 2024 annual meeting: all 8 director nominees elected and auditor ratified","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["15,222,830 shares represented at the Annual Meeting held June 18, 2024.","All 8 director nominees elected with >14.1M votes for and zero against each.","Ratification of M&K CPAs as auditor: 15,201,965 for, 9,025 against, 11,840 abstain.","Broker non-votes on director elections totaled 1,082,034 shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":5969583.778014941,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":232955,"accession_number":"0001493152-24-018507","cik":1922335,"company_name":"Syra Health Corp","ticker":"SYRA","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Syra Health Q1 revenue up 47% to $1.7M, net loss widens to $1.4M; FY2024 guidance $9-11M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $1.7M vs $1.2M Q1 2023; Population Health grew 212% YoY; Healthcare Workforce up 28%.","Net loss $(1.4M) vs $(0.8M); Adjusted EBITDA $(1.4M) vs $(0.8M).","Gross margin 10.2% (12.4% Q1 2023) due to mix shift to Healthcare Workforce.","Cash $3.2M, no long-term debt; FY2024 revenue guidance $9-11M (64-100% growth).","Awarded contracts: $660K HEDIS, $480K Indiana, $450K Shelby County, $250K DC; active in 19 states."],"consensus_eps_estimate":-0.1938,"consensus_eps_actual":-0.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":1752340.0,"consensus_period":"2024-Q1","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5969583.778014941,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":251130,"accession_number":"0001493152-24-011606","cik":1922335,"company_name":"Syra Health Corp","ticker":"SYRA","form_type":"8-K","filed_at":"2024-03-28T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Syra Health appoints COO and CFO Priya Prasad to board of directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["On March 27, 2024, Syra Health Corp. appointed Priya Prasad, its COO and CFO, as a director.","The appointment was disclosed in a Form 8-K filed with the SEC on March 28, 2024.","Syra Health is an emerging growth company listed on Nasdaq under ticker SYRA.","Prasad will continue serving as COO and CFO in addition to her new board role."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5969583.778014941,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":251129,"accession_number":"0001493152-24-011142","cik":1922335,"company_name":"Syra Health Corp","ticker":"SYRA","form_type":"8-K","filed_at":"2024-03-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Syra Health 2023 revenue $5.5M, net loss $2.94M; projects 64-100% growth in 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2023 revenue $5.5M, net loss $(2.94M), vs $5.6M and $(2.12M) in 2022.","Gross profit margin improved 670 bps to 25.6% from 18.9% in 2022 on mix shift to higher-margin units.","Adjusted EBITDA loss widened to $(2.8M) from $(2.1M); cash balance $3.3M with no long-term debt.","Guides FY2024 revenue of $9-$11M (64-100% growth), excluding potential revenue from recent Caduceus federal contract."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5969583.778014941,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":268715,"accession_number":"0001493152-23-041118","cik":1922335,"company_name":"Syra Health Corp","ticker":"SYRA","form_type":"8-K","filed_at":"2023-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Syra Health Q3 revenue up 4% to $1.58M; net loss flat at $354K; Digital Health posts first revenue","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $1.58M (+4% YoY); Digital Health unit generated first revenues of $131,356.","Population Health & Health Education revenue jumped 400% to $328,750; Healthcare Workforce at $1.1M.","Gross margin improved to 35.1% from 27.3%; net loss unchanged at ~$354K; Adj. EBITDA loss narrowed to $330K.","Secured $4.75M DC behavioral health contract (5-year) and $636K Indiana extension; launched Syrenity and CarePlus.","Closed $6.7M IPO in Oct 2023 with $4.7M net proceeds; cash on hand pre-IPO was $18,010."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.44,"consensus_revenue_estimate":null,"consensus_revenue_actual":3748943.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5969583.778014941,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":268714,"accession_number":"0001493152-23-035687","cik":1922335,"company_name":"Syra Health Corp","ticker":"SYRA","form_type":"8-K","filed_at":"2023-10-04T23:59:59+00:00","items":["5.02","5.03","8.01","9.01"],"status":"ready","headline":"Syra Health prices upsized IPO of 1.615M units at $4.125/unit, raises ~$6.7M gross","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["IPO units priced at $4.125 each: one share Class A common + one warrant (exercise $6.50, 5-year term).","Gross proceeds of approx. $6.7 million before underwriting discounts and expenses.","Shares began trading on Nasdaq on Sept 29 under ticker SYRA; IPO closed Oct 3, 2023.","Underwriters partially exercised over-allotment for 242,250 warrants at $0.01 each; option remains for 242,250 additional shares.","Five new independent directors appointed effective Oct 3: Rogers, Dahlem, V. Reddy, Paranjape, A. Reddy; committee chairs named."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5969583.778014941,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}